Loading…
Beijing hospital-drug maker focused on injectable proton-pump inhibitors and oncology injectables sold mainly to Chinese hospitals.
Beijing hospital-drug maker focused on injectable proton-pump inhibitors and oncology injectables sold mainly to Chinese hospitals.
Sells hospital injectables, led by acid-reducing injections, to public hospitals through distributors, with prices set by national volume-based procurement rounds that reward the lowest bidder. Earnings therefore depend on winning rounds rather than on brand loyalty.
In one line: A small, injectables-only Hospira.
Moat: none (distribution). Commodity hospital generics with little pricing power under national procurement tenders.
Headquarters: Beijing, China · Employees: 799
Size Beijing Aosaikang Pharmaceutical (002755.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.76B, the 1412th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.66 on 6 Nov 2026.
Performance Over six months the shares fell 25.3%, against -10.7% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 12.8% over the last twelve months (peer median +8.6%); the operating margin is 12.0% (peer median 13.1%).
Valuation It trades at 63.3× forward earnings against a peer median of 18.8× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is -14%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 15.2 points above its cost of capital (6.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.59B | CN¥1.76B | CN¥1.76B | CN¥1.43B | CN¥1.85B |
| Revenue growth | — | 0% | +23% | -23% | — |
| Gross profit | CN¥1.38B | CN¥1.38B | CN¥1.40B | CN¥1.12B | CN¥1.56B |
| EBITDA | n/a | CN¥328M | CN¥185M | -CN¥206M | -CN¥236M |
| Net income | CN¥183M | CN¥237M | CN¥160M | -CN¥149M | -CN¥226M |
| Free cash flow | CN¥141M | CN¥531M | CN¥208M | -CN¥131M | -CN¥178M |
| Capital expenditure | CN¥170M | CN¥144M | CN¥230M | CN¥129M | CN¥150M |
| Total debt | CN¥36.4M | CN¥35.3M | CN¥74.9M | CN¥127M | CN¥57.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical 002755.SZ | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% |
| China Resources Double-Crane Pharmaceutical 600062.SS | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002755.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -0.1% | 6th lowest of 21 |
| 6-month return | -25.3% | -10.7% | 3rd lowest of 20 |
| Distance from 52-week high | -37.2% | -28.4% | 5th lowest of 21 |
| Revenue growth (TTM) | -12.8% | +8.6% | 4th lowest of 19 |
| Operating margin | 12.0% | 13.1% | 9th lowest of 19 |
| Forward P/E | 63.3× | 18.8× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 14.7% | 4.9% | 5th most demanding of 15 |
| Growth delivered (Del g) | -14.0% | +10.4% | lowest of 15 |
| Hurdle (Req g minus delivered) | +28.7 pp | -2.1 pp | most demanding of 15 |
| ROIC minus cost of capital | +15.2 pp | +0.2 pp | 4th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% | +0.5% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |